Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 1,562

Document Document Title
WO/2007/030889A1
The present invention relates to a marker for the development of pre-eclampsia. In particular the invention provides a marker for the development of pre-eclampsia, which marker consists of a polypeptide of approximately 26.6 Kd as determ...  
WO/2006/086562A3
Various azetidinone derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.  
WO/2007/032634A1
The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natu...  
WO/2006/066214A3
The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of ...  
WO/2007/030890A1
The present invention relates to amniotic fluid specific polypeptide and a method for detecting rupture of the amniotic membranes. In particular the invention provides a marker for prolonged rupture of the membranes (PROM), which marker ...  
WO/2005/007831A3
The present invention provides compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like. In one aspect, the present invention relates to a protein mimetic for preventing HIV-1 entry to host cells of...  
WO/2006/103666A3
The present invention relates to a PIKK-phosphorylated BID polypeptide which can be used to induce cell cycle arrest. Specifically, the present invention provides isolated polypeptides comprising a BID amino acid sequence which can be us...  
WO/2007/021016A1
A method for photoregulating the formation of a complex between a protein of interest and a peptide capable of recognizing the protein, wherein a structural change in the peptide that is used for the recognition of the protein is photore...  
WO/2007/021253A1
The inventors have discovered that an ATPase-deficient dominant¬≠negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal stru...  
WO/2005/122379A3
The present invention provides a 4√ü1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  
WO/2006/031607A3
The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator ...  
WO/2006/096829A3
The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancre...  
WO/2006/031814A3
A method for electrochemical removal of acid-labile protecting groups on an electrode microarray using an organic solution is disclosed. The solution comprises a hydrazine derivative and a salt in an organic solvent. The hydrazine deriva...  
WO/2006/019982A3
The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease.  
WO/2006/138721A1
Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit...  
WO2004041067A3
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that ind...  
WO2005062967A3
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate mola...  
WO/2006/135371A1
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent ahs been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is clea...  
WO/2006/133196A1
The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptide...  
WO/2006/128027A1
A method is disclosed for inhibiting angiogenic activity by interacting anginex with the peptide galectin-1. Also disclosed is a method for constructing an artificial gene encoding the biologically exogenous peptide anginex and producing...  
WO2005009379A3
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative...  
WO2005086967A3
The antigen recognized by RM1 antibody is used for therapy, diagnosis and imaging.  
WO/2006/114528A1
The invention relates to the use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerisation of the aforementioned monomers of a...  
WO2005049638A3
The present invention relates to the method(s) of synthesis of and the therapeutic and cosmetic applications of biologically active peptides for improving the appearance of skin, for hastening wound healing and for treating and/or preven...  
WO/2006/111060A1
The present invention provides a method for isolating and purifying immuno-modulating polypeptide from cow placenta, which is characterized by using the steps of anion-exchange chromatography, gel exclusion chromatography and reverse-pha...  
WO2005086611A3
The present invention discloses methods of determining highly precise interactions between a membrane protein receptor and various compounds. The methods of the present invention utilize a receptophore model system and nonsense codon sup...  
WO2006024026A3
Inhibitors of the mevalonate pathway are shown to affect the phosphorylation and activation of oncogenic signaling molecules, demonstrating a mechanism for the anti-proliferative activity of such agents. Methods are provided for predicti...  
WO2002050303A3
[0083] The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and dis...  
WO/2006/098326A1
Disclosed is a complex for a biocompatible material which has no risk of causing infection with a pathogen or any adverse side effect (e.g., rejection). A complex for a biocompatible material, comprising a polypeptide comprising peptide ...  
WO2003089588A3
Novel PYRIN-2, PYR1N-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN1111 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10,...  
WO2006055623A3
Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided...  
WO/2006/090924A1
Disclosed is a drug carrier having a target-directive property, specifically a gene carrier. A peptide block copolymer having an uncharged segment and a segment derived from a polyamino acid, the uncharged segment having a terminal end c...  
WO/2006/086653A2
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastr...  
WO2005086674A3
This invention relates generally to the discovery of a novel gene, designated BRHF1. The invention further relates to the detection of the BRHF1 gene, BRHF1 expression and/or the presence of the BRHF1 protein as potential markers for the...  
WO2003087124A3
The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSAR...  
WO2005056754A3
The present invention provides methods and compositions for inhibition of drug resistance. The invention generally involves compositions that comprise achaogens, agents that inhibit a mutational process, and administration of achaogens t...  
WO2003065999A3
The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concern...  
WO/2006/079364A1
Disclosed is a method for cleaving an amide bond in a peptide chain, thereby obtaining an N-terminal peptide as a free amine and a secondary residue, as well as a peptide obtained by such method.  
WO2003085086A3
Provided herein are hybrid polypeptides that specifically bind to a disease-associated isoform of a polypeptide involved in diseases of protein aggregation. The hybrid polypeptides can be used for diagnosis and treatment of such diseases...  
WO2003084467A3
The invention relates to products and methods to elicit a targeted immune response. In particular, the invention relates to epitope constructs that comprise antigen presenting cell-targeting mechanisms.  
WO2005042699A3
Polypeptides modified by fatty acid conjugation and methods of using such modified poilypeptides in treating bacterial infections, including the treatment of antibiotic resistant bacterial infections, are disclosed.  
WO2004092197A8  
WO/2006/066358A1
The present invention relates to a plant vacuole targeting sequence X1X2X3PX4 wherein X1 is a hydrophobic amino acid, X2 is a basic amino acid, X3 is a hydrophobic amino acid, P is proline; and X4 is a hydrophilic amino acid, such as the...  
WO/2006/060871A1
The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present i...  
WO2006004620A3
The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of...  
WO/2006/056443A2
Use of an activated solid phase and a peptide-conjugated anchoring part for solid phase peptide synthesis, wherein the anchoring part is coordinatively and reversibly attached to the activated solid phase.  
WO/2006/045603A1
A novel method for on-resin formation of disulfide-borne cyclization of peptides is devised.  
WO2006023029A3
The invention features methods and compositions featuring an RSV Glycoprotein fragment for modulating an immune response in a subject.  
WO2005048944A3
The present invention relates to the field of conjugates comprising a first substrate which is attached to a least one photosensitizer and at least ont first quencher, and methods for their use. More particularly, the present invention r...  
WO/2006/042374A1
A process for separating keratinous proteins from a keratin-containing material, the process comprising the steps of: subjecting the keratin-containing material to reduction in a liquid medium to solubilise the keratinous proteins under ...  

Matches 351 - 400 out of 1,562